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1. Introduction 
1.1 Human Parvovirus B19 
Parvovirus B19 (B19V) was discovered by the Australian Virologist, Yvonne 
Cossart while screening sera from blood bank for hepatitis B virus in 1974 (1). The 
name B19 was originated from the coding of a serum sample occupying position 
19 in panel B that gave inconsistent results when it was tested for hepatitis B (1). 
B19V is a small nonenveloped virus of about 22 to 24 nm in diameter. It is 
classified as a member of the genus Erythrovirus within the family of Parvoviridae 
(2). 
1.1.1    Genomic structure and organization of B19V 
The single stranded genome includes 5,596 nucleotides (nt), composed of an 
internal coding sequence of 4,830 nt flanked by the terminal repeat sequences of 
383 nt each (3). The B19V genome has two large open reading frames, with the 
two capsid proteins VP1 and VP2 encoded by genes on the right side and the 
single nonstructural protein (NS1) encoded by genes on the left side of the 
genome. Transcription is capable for producing at least nine overlapping mRNA 
transcripts, all of them arise from the single P6 promoter at the extreme left side of 
the genome (3-5). The most important viral proteins include the major nonstructural 
protein NS1 and the two structural proteins VP1 and VP2 (5, 6).  
1.1.1.1   Nonstructural protein and capsid proteins 
The major nonstructural protein, NS1 (nt 435 to 2448) has a molecular mass of 77 
kDa (5-8). The NS1 protein may function to have site specific DNA binding, DNA 
nicking, ATPase, transcriptional, and helicase activities (9-13), transactivator of 
cellular and viral promoters (14), stimulator of apoptosis (15-17), and modulates 
inflammatory signaling by activation of the STAT3/PIAS3 pathway (18).  
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The B19V genome further encodes the structural capsid proteins VP1 and VP2 (6), 
which are decisive for the viral life cycle (19, 20). The VP2 protein is encoded by 
sequences from nt 3125 to 4786 and has a molecular mass of 58 kDa. VP1 is the 
minor capsid protein encoded by the sequence from nt 2444 to 4786 and is 
identical to VP2 with the addition of 227 amino acids (termed the VP1 unique 
region) at the amino terminus (7, 8). The VP1 has a molecular mass of 84 kDa and 
makes up 4% of the total capsid protein (7). 
The VP1 protein contains a sequence similar to secreted phospholipase A2 
(sPLA2) (21-23), which probably generates eicosanoids (23, 24). The vPLA2 
enzyme activity is disrupted by replacement of a histidine at position 153 with 
alanine (H153AVP1) (23, 24).  
 
Figure 1: Transcription map of the major genes and resulting transcripts of B19. The nonstructural protein NS1 
arises from the single unspliced transcript on the left-hand side of the genome (hatched areas). The capsid proteins 
VP1 and VP2 are encoded by genes with overlapping reading frames from the right -hand side of the genome , aa 
denotes amino acids, nt nucleotides, (1), (2), and (3) reading frames, and P6, the single viral promoter (25). 
1.1.2   Pathophysiology 
The life cycle of B19V is similar to other nonenveloped DNA viruses in binding of 
the virus to the receptors of the host cell, internalization, translocation of the 
genome to the host nucleus, DNA replication, RNA transcription, assembly of 
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capsids and packaging of the genome, and finally lysis of the cell with release of 
the mature virions (2).  
 
             Figure 2: Schematic life cycle of Parvovirus B19 (2) 
 B19V replicates in erythroid progenitor cells (26) and has been shown to cause 
agglutination of human red cells (27) and to bind to blood group P antigen in 
erythroid progenitor cells, as measured by hemagglutination (26). In tissue culture 
anti-P monoclonal antibody has blocked infection of erythroid progenitors with 
B19V. Erythrocytes lacking P antigen are not agglutinated with B19 thus 
demonstrating that P antigen is the B19V receptor (26). P antigen is present also 
on megakaryocytes, endothelial cells, placenta and fetal liver. The tissue 
distribution of P antigen is consistent with the clinical syndromes caused by 
parvovirus B19. People lacking P antigen are resistant to B19 infection (28). 
B19V may enter cells by binding to blood group P antigen (29), α5β1 integrin and 
Ku80 autoantigen (30, 31).  B19V thus preferably invades erythroid progenitor cells 
but may enter fetal myocytes, follicular dendritic cells and endothelial cells (29-32). 
In fatal inflammatory cardiomyopathy the virus is particularly abundant in 
endothelial cells (33, 34).  
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1.1.3 Prevalence and Incidence 
B19V is a worldwide infectious pathogen in humans. The estimated prevalence of 
IgG antibodies directed against B19V ranges from 2 to 15% in children at age of 1 
to 5 years old, 15 to 60% in children aged 6 to 19 years old, 30 to 60% in adults, 
and more than 85% in the geriatric population (35-38). Women of the childbearing 
age have an annual seroconversion rate of 1.5% (39).  
1.1.4 Transmission 
Transmission of B19V infection can occur through the respiratory route, blood 
derived products administered parenterally, and from mother to fetus. The virus is 
generally spread in the community by a respiratory route as B19V specific DNA 
has been detected in the respiratory secretions at the time of viremia. The case to 
case interval is 6 to 11 days irrespective of the type of B19V related disease (2). 
Transmission from the mother to the fetus occurs in one third of cases involving 
serologically confirmed primary maternal infections (40). Nosocomial transmission 
has been shown infrequently (41). The transmission can also occur among staff in 
laboratories handling native virus (42).  
1.1.5 Diseases associated with B19V  
B19V diseases primarily involves infection in the healthy host manifested as fifth 
disease (erythema infectiosum), arthralgia, hydrops, myocarditis, neurologic 
disease, hepatitis as well as hematologic symptoms in predisposed individuals (2). 
1.1.5 .1 Asymptomatic infection  
The presence of subclinical B19V infection is a common finding in both children 
and adults. In 1989, it has been shown that quarter of infected persons had no 
recollection of specific symptoms (43) and In 1991, it has been shown that fewer 
than 50% of IgM-positive women show signs of rash or arthralgia (44). 
Asymptomatic seroconversion following recent transfusion in patients with 
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hemolytic anemia suggests that symptoms can be hidden by transfusion of 
erythrocytes with a longer life span than the defective erythrocytes of the host (45). 
1.1.5.2 Fifth disease 
Fifth disease is also known as Erythema infectiosum or slapped cheek disease. It 
is the commonest manifestation of B19V infection in children (46). The association 
with B19V has been identified Following an outbreak of fifth disease by the 
discovery of specific IgM in specimens from the involved patients (2). The disease 
starts with prodromal symptoms which often unnoticed including fever, coryza, 
headache and nausea. It is characterized by a facial erythema of medium intensity 
appearing in the cheeks with relative circumoral pallor (slapped cheek appearance) 
beginning 18 days after infection. The second stage is composed of a rash 
appearing in the limbs and trunk occurs 1 to 4 days later. The rash is reticular and 
composed of pink maculae that usually undergo a central fading, which causes the 
rash to develop a festooned appearance. The rash can be transient or recurrent, 
and the difference in intensity can be linked to environmental factors such as heat 
and exposure to sunlight (47). Other symptoms include scaly dermatitis, itching, 
vesicles (43, 48).  
1.1.5.3 Arthropathy 
The association between arthropathy and B19V infection has been identified in 
1985 (49, 50). The incidence of arthralgia is approximately 10% or less in children 
with fifth disease, while 19% of children with recent arthritis have evidence of 
recent B19 infection (51).  
Arthralgia and arthritis are the most prevalent manifestations of primary B19V 
infection in adults affecting 30% of males and 60% of females, while the dermal 
affection is less frequent and not characteristic in the adult population (43, 46, 52). 
The arthropathy is likely to be immunologically mediated since the onset exists with 
the appearance of circulating antibodies. Joint symptoms present as an acute 
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moderately severe peripheral polyarthritis involving the metacarpophalangeal joints 
(75%), wrists (55%), knees (65%), and ankles (40%) without articular erosions 
(53). About 50% of patients with chronic B19V arthropathy meet the criteria of the 
American Rheumatoid Association for a diagnosis of rheumatoid arthritis (54, 55).  
1.1.5.4 Hydrops fetalis 
It has been shown that B19V cause nonimmune hydrops fetalis (56). Fetal B19V 
infection may also cause fetal or congenital anemia, abortion, or stillbirth or result 
in an asymptomatic self limiting episode (2). It has been reported that B19V cause 
congenital malformations (57, 58). The pathogenesis of fetal damage is similar to 
that of patients with aplastic crisis in which the erythrocytes have a reduced life 
span. Erythroblasts in the fetal liver exhibit signs of B19V infection (59, 60). Fetal 
infection is persistent and characterized by severe anemia, high output cardiac 
failure, and death (61). Impaired circulation caused by fetal myocarditis may 
contribute to the accumulation of fluids (62). 
The incidence rate of B19V infection during pregnancy is about 1 to 5% (63-65). 
The risk of developing hydrops following B19V infection is ranging from 0 to 24% 
(66-72), however, in pregnant women with a confirmed primary infection, the risk of 
an abnormal outcome is about 5 to 10% (40, 67, 71). The possblity of an adverse 
fetal outcome after infection is greatest between 11 and 23 weeks of gestation, 
which correlates with the hepatic period of hematopoietic activity (73, 74). 
Cordocentesis can give precise assessment of fetal anemia, which can be then 
corrected by intravenous transfusion of erythrocytes (75). 
1.1.5.5 Myocarditis 
B19V infection of cardiac endothelial cells may result in isolated left ventricular 
diastolic dysfunction (76) and is an important pathogenic agent in the etiology of 
inflammatory cardiomyopathy (iCMP) (77). B19V infection may occur during 
pregnancy leading to maternal and fetal myocarditis, congenital malformations, 
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stillbirth and abortion (78-81). The consequences of antenatal infections are 
particularly severe as B19V preferably enters proliferating cells (82). B19V thus 
preferably invades erythroid progenitor cells but may enter fetal myocytes, follicular 
dendritic cells and endothelial cells (29-32). In fatal inflammatory cardiomyopathy 
the virus was particularly abundant in endothelial cells (33, 34). B19 infection has 
been shown to cause general disease in pediatric cardiac transplant recipients (83, 
84) as well as possible myocarditis (85, 86). 
1.1.5.6 Neurologic disease 
Association of neurologic symptoms with erythema infectiosum has been identified 
(87, 88). B19V DNA have been detected in cerebrospinal fluid in fatal 
encephalopathy (89) and aseptic meningitis (90). B19V antibodies were detected in 
complex regional pain syndrome (91). Neuralgic amyotrophy has been reported 
following B19V infection (92).  
1.1.5.7 Hepatitis 
B19V was first identified in a sample sent for hepatitis testing (2). B19V might 
cause hepatitis (93), transient disturbance of consciousness, hepatic dysfunction 
(94) , fulminant liver failure before or immediately after liver transplantation in 
children (95), acute hepatitis or hepatic disorder after B19 infection in adults (96).  
1.1.5.8  Transient aplastic crisis  
Transient aplastic crisis was the first disease to be associated with B19V. It is 
characterized by a short self limited episode of pure red cell aplasia which had 
been shown in patients with hemolytic anemia, however, any person suffering from 
decreased erythrocyte production or increased destruction or loss of erythrocytes 
might  be in risk of developing aplastic crisis following B19V infection (2). 
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Moreover, conditions associated with decreased erythrocyte production predispose 
for the development of B19V induced aplastic crisis including iron deficiency(2), 
congenital dyserythropoietic anemia (97), and α- and β-thalassemias (98-101). 
B19V may also cause transient aplastic crisis in patients with increased erythrocyte 
destruction or loss diseases including hereditary spherocytosis (98, 101, 102), 
hereditary stomatocytosis (103), pyruvate kinase deficiency (104), pyrimidine-5′-
nucleotidase deficiency (105), sickle cell disease (45, 98, 106), chronic 
autoimmune hemolytic anemia (100) and paroxysmal nocturnal hemoglobinuria 
(107).  
1.1.5.9 Congenital anemia  
It was reported that three infants with hydrops have congenital anemia due to 
transplacental B19 infection (108). B19V DNA has been detected in 3 of 11 Bone 
marrow smears, and giant pronormoblasts showed low sensitivity (33%) and poor 
specificity (75%) in children diagnosed with Diamond-Blackfan anemia which is a 
congenital anemia disorder (109). In another report, an infant developed congenital 
anemia due to a possible B19V infection (110).  
1.1.5.10 Thrombocytopenia and Neutropenia 
B19V infection may cause subclinical or overt thrombocytopenia in patients (46, 
111-113). Recent B19V infection has been shown in 6 of 47 pediatric idiopathic 
thrombocytopenic purpura patients (ITP) (13%) and it has suggested that children 
with ITP and associated B19V infection are characterized by acute onset of 
thrombocytopenia. Among the B19V positive children, the duration of the illness 
was short in three children treated with immunoglobulin but chronic in the 
remaining three patients given high dose of steroids (114). 
Examination of the bone marrow has showed that Parvovirus B19V infection might 
be a common cause of immune mediated neutropenia in childhood (115).  
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1.1.5.11 Transient erythroblastopenia of childhood 
Transient erythroblastopenia of childhood (TEC) is a disorder characterized by 
anemia, reticulocytopenia, and decreased red blood cell precursors in the bone 
marrow aspiration affecting young children, age 3 to 4 years. TEC is a common 
cause of red cell aplasia in immunocompetent children. Due to its hematopoietic 
effect, B19V might be involved in this disorder (116-118).  
1.1.6   Diagnosis of B19V  
1.1.6.1  Diagnostic Cytopathology 
The presence of giant pronormoblasts in either peripheral blood or bone marrow is 
suggestive of B19V infection, however, their presence or absence should not be 
considered as the only criteria for diagnosis of B19V infection (2). 
1.1.6.2  Detection of B19 Virus 
 
B19V can be detected by isolation of viral DNA using direct hybridization or PCR 
methods. Direct hybridization as a slot blot or dot blot format, generally employs an 
almost full length viral DNA probe labeled with 32P, digoxigenin or biotin to bind to 
DNA in clinical specimens (119, 120). Direct hybridization is very sensitive to 
detect B19V levels in acute transient aplastic crisis (2).  
PCR has increased the sensitivity of DNA detection (121-123). DNA can be 
detected for extended periods of time in serum (124-126), synovial membranes 
(127) and bone marrow (128). Detection of low levels of B19V DNA alone cannot 
be used for diagnosing acute B19V infection (2).  
1.1.6.3  Detection of Antibodies 
B19V IgM has been detected in over 85% of clinical cases of fifth disease and 
aplastic crisis With the IgM ELISA method. B19V IgG antibodies prevalence is 
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increased according to age. About 2% of children less than 5 years of age and 
49% of adults greater than 20 years of age had B19V IgG antibodies. 
The B19V antibody ELISAs are specific and sensitive tests to detect B19 infections 
(35).  
1.1.7  Treatment  
In most cases, patients with fifth disease do not need any treatment while some 
patients with B19V arthralgia might need symptomatic treatment (anti-inflammatory 
drugs). The prognosis of transient aplastic crisis caused by B19V can be good by 
erythrocyte transfusion which improve the hemoglobin concentration (129). B19V 
infection in pregnant seronegative women must be monitored by weekly ultrasound 
examinations and cordocentesis. The mortality of hydrops fetalis can be lowered 
by intrauterine transfusions (75). The most Effective treatment for persistent B19V 
infection (pure red cell aplasia) is infusion of immunoglobulin (0.4 g/kg of body 
weight/day for 5 days or 1g/kg/day for 2 to 3 days). This treatment is very often 
curative leading to a marked rise in reticulocyte count and rise in hemoglobin 
concentration (130-133).  
1.2 Potassium channels 
Membrane proteins represent about 30% of the total proteome of an organism and 
the half of this number is carrier proteins and ion channels. Potassium ion channels 
are considered to be the most diverse and the predominant class of membrane 
proteins(134). The potassium channels are classified depending on the primary 
structure and the function into: voltage gated (Kv) channels, inwardly rectifying 
channels (Kir), Ca2+-activated channels (KCa) and two-pore domain (K2P). Kv 
channels are the most diverse group of the potassium channels (135). 
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1.2.1  Voltage Gated Potassium Channels Kv1.3 and Kv1.5 
Voltage gated K+ channels (Kv), a superfamily that include 12 subfamilies (Kv1-
Kv12), contribute to the maintenance of resting membrane potential and the control 
of action potentials (136).The voltage gated K+ channels Kv1.3 and Kv1.5 are 
members of the Shaker (Kv1) family of K+ channels and are involved in tissue 
differentiation and cell growth (137).  
1.2.1.1  Structure of Kv Channels 
All Kv channels share high level of similarity. Each Kv channel gene encodes one 
α-subunit (Kvα).  Each four α-subunits form a functional channel. Kv channels are 
usually homotetrameric in structure (with all Kvα being identical) (138, 139), 
however, some channels can be heterotetrameric (with two or more non-identical 
Kvα subunits) (140). 
The transmembrane domain of the Kv channel α-subunit is composed of six 
helices: S1-S6 These helices form two structurally and functionally different parts 
of the tetrameric channel: pore domain which is a potassium ion conducting 
domain formed by helices S5-S6 located in the channel center and voltage sensing 
domain, VSD which is sensible to changes in the membrane potential formed by 
helices S1-S4 located on the channel periphery (140). 
The pore part has a channel gate and a selective filter that does not allow ions 
other than K+ to pass through the channel. The channel gate is created by crossing 
C-termini of the S6 helices that block passage of ions when the channel is closed 
(141-143). The selective filter is formed by a conserved fragment (P-region) and a 
S5-S6 loop (140).  
The pore domain and voltage-sensing domain (VSD) are covalently bound by the 
S4-S5 linker which is an amphiphylic helix connected to the C-terminus of S6 helix 
(S6T) and the next subunit (140, 144-148). The highly conserved region of the S6T 
helix plays an important role in the opening and closing of the channel. It is a 
flexible region which allows the channel to open (140).  
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Kv channels have two gates: the upper gate formed by the P-loop of the selectivity 
filter on the extracellular side and the lower gate formed by crossing the S6 helices 
on the intracellular side. In the Kv channels, lower gates are the main activation 
gates which are controlled by external stimuli, such as the membrane potential 
(140). Kv channels also have a cytoplasmic part which is formed by N- and C-
termini beside the transmembrane part  (149). 
 
 
Figure 3: Structure of Kv channels. A. Scheme of a single α-subunit of the Kv channel. Transmembrane segments 
S1–S6 and pore-forming P-loop are marked. Charged Arg of the membrane voltage sensor S4 are marked with “+” 
signs. PD–pore domain. B. Crystal structure of a single α-subunit of the Kv1.2 channel. S1–6 segments, cytoplasmic 
domain T1, linker connecting the transmembrane portion with the T1 domain (T1–1), as well as N- and C-termini are 
marked. Charged Arg residues of the membrane voltage sensor S4 are indicated by blue circles. C. Crystal structure 
of the Kv1.2 channel in a complex with the β-subuni. TM –transmembrane region. D. Gate of the Kv2.1 channel. (140, 
150) 
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1.2.1.2 Expression and characteristics of Kv1.3 and Kv1.5 
Kv1.3 was first cloned from brain tissue, and its expression is widely distributed 
throughout the body (151, 152). it is highly expressed in lymphocytes and the 
olfactory bulb (153), and it is also expressed in the hippocampus (154), adipose 
tissue (155), both skeletal and smooth muscle (156-158), epithelia (159) and 
endothelium (160). 
Kv1.3 currents have both characteristic cumulative inactivation and a marked C-
type inactivation. The single channel conductance of Kv1.3 is 13 pS and the 
voltage which is required for activation of Kv1.3 channel is -35 mV (161). 
Unlike the Kv1.3 channel, the first site for isolation of Kv1.5 channel was the 
human ventricle and Kv1.5 is expressed in the atria (162). Like the Kv1.3 channel, 
Kv1.5 channel is also ubiquitously expressed (151, 152). Kv1.5 is expressed in 
skeletal and smooth muscle (156-158). Kv1.5 is abundantly expressed in 
endothelial cells (163) and  to a lesser extent in the brain (164, 165).  
Kv1.5 currents take part in  the ultra-rapid activating K+ current in the heart known 
as Ikur, which has a role in the repolarization of an action potential (166). The 
conductance of the Kv1.5 channel is 8 pS and the voltage required for its activation 
is about 24 mV. In contrast to Kv1.3, the inactivation Kv1.5 is slow and without 
cumulative inactivation (161).  
1.2.1.3 Functions of Kv1.3 and Kv1.5 K+ channels 
Kv1.3 and Kv1.5 channels play a role in many cellular processes including 
maintenance of vascular smooth muscle tone (167), cell growth (168), regulation of 
cell volume (169) apoptosis (170, 171), adhesion (172), mobility, epithelial 
transport (173), proliferation (174), insulin release (155) and homeostasis(175). 
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1.2.1.4  Pharmacology   
Kv1.3 and Kv1.5 are inhibited by the general K+ channel blockers 4-aminopyridine 
(4-AP) and tetraethylammonium (TEA) (176). Another potent inhibitor for these 
channels is Psora-4 which has lesser effect on the rest of the Kv isoforms (177). 
The highly specific toxins such as charybdotoxin and margatoxin (178, 179) and 
anemone peptide ShK and their derivatives (180) are known to be highly effective 
for Kv1.3. Kv1.5 is not sensitive to Kv1.3 blockers and has no known specific 
pharmacology but new chemicals such as S0100176 (from Sanofi-Aventis) (181) or 
diphenyl phosphine oxide-1 (DPO-1) have been discovered to be potent inhibitors 
for Kv1.5 (182). 
1.2.1.5 Abnormalities 
Impaired expression of Kv1.3 in T effector memory cells is involved in the onset of 
juvenile multiple sclerosis (183). The deficiency of Kv1.3 alters insulin sensitivity 
and glucose tolerance (184). On the other hand, Kv1.5 loss of function mutations 
might cause atrial fibrillation (185). 
1.3 Inwardly rectifying Kir2.1 Potassium channel 
Kir2.1 was the first member of classical Kir channels (Kir2.X) family to be cloned 
and it has been cloned from a mouse macrophage cell line and named 
IRK1/Kir2.1/KCNJ2 (186).  
It was thought that  Kir2.x subunits are made up of homomeric complexes(187). 
However, it has been shown that Kir2.x subunits can function as heterotetramers in 
vitro and in vivo. In vitro electrophysiological experiments have revealed that each 
of Kir2.1, Kir2.2, and Kir2.3 can assemble with any one of the other subunits, and 
the respective heteromer has different properties from that of their homomers 
(188).  
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1.3.1 Structure of Kir2.1 
The basic structure of classical Kir channels is composed of transmembrane and 
cytoplasmic regions and pore structure (189). The inward rectification is due to 
intracellular ions such as Mg2+ (190, 191) and polyamines (192, 193).  
Further site-directed mutagenesis recognized negatively charged amino acids 
(Glu) at two different positions (E224 and E229 for Kir2.1) in the COOH terminus of 
the cytoplasmic domain that are involved in both Mg2+ and polyamine sensitivity 
(194-197). It has been suggested by Mutagenesis and substituted cysteine 
accessibility experiments that these residues directly interact with Mg2+ and 
polyamines (198, 199).  
The crystal structure of the cytoplasmic domain of Kir2.1 is composed of an 
intrinsically flexible loop around the membrane face of the cytoplasmic pore (200). 
The loop narrows the cytoplasmic pore to about 3 A and forms a girdle around the 
central pore axis. The girdle consists of a loop between βH and βI strands and is 
known as the G-loop forms the narrowest portion of the ion conduction pathway in 
the cytoplasmic region. The narrowest part of the G-loop is formed by A306 and to 
a lesser extent by E299, G300, M301, and M307. A306 is located at the apex of 
the G-loop. The Charged amino acids, R228, D255, D259, and R260, face the 
cytoplasmic pore (189, 200). 
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Figure 4: The structure of the cytoplasmic pore region of Kir2.1. Side (left and bottom right) and top -down (topright; 
membrane to cytoplasm) views of the cytoplasmic region (NH2 and COOH termini) of the Kir2.1 structure, 
highlighting amino acids lining the permeation pathway. Cβ atoms (A306) of the G-loop make up the narrowest  
about 3-Å region of the pore and are shown as open circle s for clarity. Other residues near the G-loop are 
labeled.(189, 200) 
1.3.2 Factors regulating the activity of Kir2.1 
PKA activators had small effect on Kir2.1 currents (201). The current of Kir2.1 has 
increased by cAMP when the channel was coexpressed with A kinase-anchoring 
protein 79 (AKAP79) and treated with the phosphatase inhibitors okadaic acid or 
cypermethrin (202). Classical Kir channels reconstituted with injection of brain 
poly(A)+ RNA into Xenopus oocytes has been shown to be inhibited by 
isoproterenol, a β-adrenergic agonist (203). This effect is exerted by the increase 
of intracellular cAMP and also cGMP (203). 
Cytoplasmic regulatory factors such as phosphorylation and pH regulate channel 
function by affecting the channel-PtdIns(4,5)P2 interaction. Kir2.1 interacts more 
strongly with PtdIns(4,5)P2 (204).  
Activity of Kir2.1 on the cell surface can be negatively regulated by its 
internalization, which is dependent on GTPase Rho family proteins. Kir2.1 
expresses a high degree of internalization mediated by dynamin, a protein 
essential for endocytosis (205, 206).  
Other Kir2.1 regulators include arachidonic acid (207), phosphatidylinositol 4,5-
bisphosphate PI(4,5)P2 (208, 209), cholesterol(210), tyrosine kinase 
phosphorylation(211), TNF-alpha (212), Chapsyn 110 (206) and filamin-A (213),  
1.3.3   Overview of Physiological Functions of Kir2.1 in Organs 
1.3.3.1   Heart 
The classical Kir current IK is highly expressed in cardiac myocytes, including 
Purkinje fibers, ventricular and atrial tissues (214-217) but it is absent in nodal cells 
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(218). IK play critical role in determining the shape of the cardiac action potential, 
setting the resting potential, permitting the plateau phase and  inducing rapid final 
stages of repolarization (189). Kir2.1 might be the core subunit that generates the 
IK current (219). 
1.3.3.2  Blood vessels 
Endothelial and smooth muscle cells are the major components of vasculature 
(189). Electrophysiological studies have shown that classical Kir channels are 
expressed in both Endothelial and smooth muscle cells (220, 221). Classical Kir 
channels are the most prominent channels in vascular endothelial cells (221-223). 
The Functional expression of classical Kir channels provides the driving force for 
Ca2+ influx through Ca2+-permeable channels by seting the Eres of endothelial cells 
to a negative potential. Blockage of endothelial Kir channels by Ba2+ inhibits both 
flow-induced Ca2+ influx and vasodilatation caused by Ca2+-dependent production 
of Nitric Oxide (224, 225).  
Kir2.1 was identified in vascular smooth muscle cells but neither Kir2.2 nor Kir2.3 
was identified there (226). Blood vessels in Kir2.2 knockout mice dilated normally 
in response to high extracellular potassium stimulation but not blood vessels from 
Kir2.1 knockout mice (227). Therefore, Kir2.1 might be the main subunit to which 
form the classical Kir current in vascular smooth muscle (227). 
1.3.3.3  Neurons in the brain  
Kir currents were detected in hippocampal neurons (228) and neonatal rat spinal 
motor neurons (229). The currents which are generated by Kir2.x subunits play an 
important role in the maintenance of Eres and regulation of the excitability of the 
neurons. Ba2+ block of Kir channels in an isolated neuron caused depolarization 
and initiated the firing of action potential (230). 
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In situ hybridization histochemistry and immunohistochemistry had showed that 
that classical Kir channels including Kir2.1 are abundantly and differentially 
expressed in the whole brain (231). 
Kir current has been recorded in Schwann cells surrounding peripheral nerve fibers 
(232). Kir2.1 and Kir2.3 are expressed in the microvilli of Schwann cells at the 
nodes of Ranvier (233). As the villi are facing towards the axon, these Kir channels 
may contribute in maintaining extracellular potassium by absorbing excess K+ 
released from excited axons. This function is essential for maintaining proper 
function of nerve fibers (233).  
1.3.3.4  Skeletal muscle 
Classical Kir channels play a role in setting the Eres and shift it toward the direction 
of hyperpolarization. Kir2.1 is expressed in skeletal muscle (234). The importance 
of Kir2.1 in muscle function has been revealed by analysis of Andersen's 
syndrome. A decrease of the Kir2.1 conductance result in depolarization of the Eres, 
leading to inactivatation of Na+ channels and thus prevent initiation and 
propagation of action potentials (235). 
The functional expression of Kir2.1 is necessary for differentiation of myoblasts 
(236) and for the fusion of mononucleated myoblasts to form a multinucleated 
skeletal muscle fiber (237). Kir2.1 induce hyperpolarization which maintain the 
membrane potential in a range where Ca2+ can enter the myoblasts through Ca2+ 
permeable channels promoting the differentiation and fusion of myoblasts (237).  
1.3.3.5   KIDNEY 
Kir2.1 is found in juxtaglomerular cells and it is not found in epithelial cells or 
glomeruli (238). Kir2.1 plays a major role in setting the membrane potential in the 
juxtaglomerular cells (238). 
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Activation of Kir2.1 in proximal renal tubules increases the electrical driving force 
for electrogenic bicarbonate exit across the basolateral cell membrane leading to 
cytosolic acidification and subsequent stimulation of the apical Na+/H+ exchanger 
and thus increases Na+ entry And the demand for Na+ extrusion through the Na+/K+ 
ATPase (239). 
1.3.4 Abnormalities 
1.3.4.1 Andersen’s Syndrome (LQT type7)  
Andersen's syndrome is characterized by cardiac arrhythmias of long Q-T 
syndrome (LQT7), dysmorphic bone structure in the face and fingers and periodic 
paralysis (240). It is an autosomal dominant disorder due to loss of function 
mutations in the KCNJ2 gene which encodes the Kir2.1 subunit (235). These  
mutations induce dominant negative effects on the K+ current (241, 242) by 
impairing the interaction between the channels and PtdIns(4,5)P2 (243) or by 
inhibiting trafficking of Kir2.1 to cell membrane surface (241). Cardiac Arrhythmias 
in Andersen's syndrome is due to reduction of Kir2.1 function that prolongs the 
plateau phase of the action potential and depolarizes the resting membrane 
potential. Abnormal bone structure can be caused by the dysfunction of 
osteoclasts. Since the Low extracellular pH in the extracellular matrix is maintained 
by H+ secretion by a proton pump is critical for proper functioning of the osteoclasts 
and as this H+ secretion is achieved in exchange for K+ transport through Kir2.1 
channels, disruption of Kir2.1 channels can cause osteoclast dysfunction which 
can lead to severe bone deformity(189).  
1.3.4.2 Short Q-T syndrome 
The short Q-T syndrome which is associated with a high incidence of sudden 
cardiac death, syncope, and/or atrial fibrillation even among newborns and young 
patients due to gain of function mutation affecting the Kir2.1 gene (244).  
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1.4 Aim of the study 
B19V infection is common in humans (245). B19V infection is associated with 
myocarditis (246, 247). Endothelial B19V infection may lead to isolated left 
ventricular diastolic dysfunction (76) and B19V associated myocarditis thus 
causing an endothelial cell mediated disease (248). In pregnancy B19V-infection 
may be followed by maternal and fetal myocarditis, congenital malformations, 
stillbirth and abortion (78-81). B19V preferably invades into proliferating cells thus 
causing particularly severe disorders during antenatal infection (82). Endothelial 
rather than myocardial B19V genomes were detected in fatal inflammatory 
cardiomyopathy (33, 34). 
The B19V genome encodes the structural capsid proteins VP1 (6) VP1 contains a 
sequence homologous to the catalytic site and Ca2+-binding loop of secreted 
phospholipase A2 (sPLA2) (21-23). The vPLA2 enzyme activity is disrupted by 
replacement of a histidine at position 153 with alanine (H153AVP1) (23, 24). 
Expression of VP1 but not of H153AVP1 in endothelial cells upregulates Ca2+ entry 
(249), an effect mimicked by PLA2 product lysophosphatidylcholine (249). VP1 has 
further been shown to inhibit Na+/K+ ATPase activity (250), an effect abrogated by 
loss of function mutation of the PLA2 sequence and mimicked by 
lysophosphatidylcholine (250, 251).  
The aim of  present study is to explore whether expression of VP1 influences the 
activity of the Potassium channels Kv1.3 and Kv1.5, which are expressed in the 
endothelium (160, 163) and are critically important for proliferation in several cell 
types (252, 253) and whether expression of VP1 influences the activity of the 
inwardly rectifying Kir2.1 K+ channels, which have previously been shown to be 
expressed in endothelial cells (221). Moreover, to explore whether the effect of 
VP1 on Kv1.3, Kv1.5 and Kir2.1 Potassium channels is sensitive to inhibition of 
PLA2 and is mimicked by lysophosphatidylcholine.  
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2. Material  
2.1. Two electrode voltage clamp 
2.1.1.  Technical equipments 
Name                                                            manufacturer and country of origin 
Autoclave HICCAVE-50 HMC          System labor systemtechnik, Wettenberg,  
                                                         Germany. 
Digitizer digidata 1322A                   Axon Instruments, Union City, CA, USA 
DMZ universal puller                        Zeitz-instruments, Martinsried. Germany. 
Eppendorf centrifuge 5415R            Hinz gmdh. Hamburg. Germany 
Eppendorf pipettes 0.1-1000ul         Eppendorf. Hamburg. Germany. 
Gene clamp 500 amplifier                Axon Instruments, Union City, CA, USA 
Maclab D/A converter                      AD instruments, Castle Hill, Australia. 
Nanoliter injector 2000                    World precision instruments, Berlin, Germany. 
pH meter 646                                  Carl Zeiss, Oberkochen. Germany 
Safety cabinet class II(Hera safe)     Kendro laboratory products, Langenselbold, 
                                                     Germany        
 
2.1.2   Stock materials 
Name                                                            manufacturer and country of origin 
Borosilicate glass capillaries (injection)               Harvard apparatus, USA 
(External diameter: 1.14mm,  internal diameter: 0.5mm) 
Borosilicate glass capillaries (measurement)      Harvard apparatus, USA. 
(External diameter: 1.5mm,   internal diameter: 1.17mm) 
Milipore express plus high flow rate                     Milipore, Schwalbach, Germany. 
membranes (PES). 73mm/0.22um. 
Combitips plus 2.5 ml                                           Eppendorf, Hamburg, Germany 
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Eppendorf tubes                                                   Eppendorf, Hamburg, Germany 
Falcon tubes (50ml)                                             Greiner bio-one, Frickenhausen, 
                                                                            Germany     
 
 
2.1.3  Software 
Name                                                            manufacturer and country of origin 
Microsoft office 2002 SP3                      Microsoft corp. Redmond, USA. 
Microcal Origin 6.0G                              Microcal software, Northampton, MA, USA. 
GraphPad InStat v3.05                          GraphPad Software Inc., La Jolla, CA, USA 
pClamp 9.0 software package               Axon Instruments, Union City, CA, USA. 
MacPyMOL 1.3 (Open source)              DeLano Scientific, Schödinger, LLC. USA.                                                                                     
 
2.1.4  Chemicals 
Name                                           Manufacturer and country of origin 
Acetone                                         Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
CaCl2 x 2H2O                                 Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
Collagenase Type II                      Worthington Biochemical Corp., NJ, USA. 
HEPES                                          Carl Roth GmbH, Karlsruhe, Germany. 
KCl                                                Carl Roth GmbH, Karlsruhe, Germany. 
Methanol                                       Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
MgCl2 x 6H2O                                Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
NaCl                                              Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
Paraffin                                          Merck, Darmstadt, Germany. 
Sodium pyruvate                           Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
Theophylin (Euphylon ©)               Nycomed GmdH, Konstanz, Germany. 
Phenphormin hydrochloride          Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
Tetracycline                                  Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
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Ciprofloxacin                                 Fresenius Kabi Austria GmdH, Austria. 
Gentamycinsultaf                          Merck Serono, Dramstadt, Germany.    
(Refobacin ©)   
Actinomycin D                          Sigma-Aldrich Chemie GmbH, Steinheim, Germany. 
L-α-Lysophosphatidylcholine    Sigma-Aldrich Chemie GmbH, Steinheim, Germany.  
Ouabain Octahydrate               Calbiochem, Darmstadt, Germany.     
 
2.1.5 Solutions 
 ND96 ND96-A OR2 OR2-Collagenase 
NaCl 96 88.5 82.5 82.5 
KCl 2 2 2 2 
CaCl.2H2O 1.8 1.8   
MgCl2.6H2O 1 1 1 1 
HEPES 5 5 5 5 
Sodium pyruvate  5   
Tetracyclin  0.11   
Ciprofloxacin  0.004   
Refobacin  0.222   
Theophylin  0.498   
Collagenase    2 mg/ml 
pH 7.4 7.5 7.4 7.4 
Table 1: Composition of solutions used for two-electrode voltage clamp 
experiments (in mM unless stated otherwise) 
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3. Methods 
3.1 Preparation of cRNA 
 
B19V DNA was isolated from deparaffinized myocardial tissue of a patient with 
fatal B19V-associated inflammatory cardiomyopathy after proteinase K digestion, 
phenol/chloroform extraction and ethanol precipitation (accession number: 
DQ225150). Constructs encoding wild-type VP1 (250), PLA2-negative H153AVP1 
mutant (250), mouse Kv1.5 (254), mouse Kv1.3 (255) wild-type Kir2.1 (256) were 
used for generation of cRNA 
 
 The cRNA synthesis protocol consists of two steps: 
1. Linearization of the plasmid DNA containing the sequence of interest. 
2. Generation of cRNA itself. 
 
3.1.1 Plasmid DNA linearization 
Endonucleases were used to obtain a cut at the 3' end of the insert. Specific 
restriction enzymes as shown in table 2 were used to linearize specific plasmids. 
 
Table 2: Plasmids containing the desired genes encoding for specific 
proteins and restriction endonuclease enzymes used to linearize each 
plasmid. 
 
Protein 
 
Plasmid 
 
Restriction 
Endonuclease 
 
Kv1.3 
 
pSP64T 
 
EcoR I 
 
Kv1.5 
 
pBluescript SK 
 
BamH I 
 
Kir2.1 
 
pGHJ 
 
Mlu I 
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VP1 
 
pGHJ 
 
Xba I 
 
H153AVP1 
 
pGHJ 
 
Xba I 
 
The reaction mixture as presented in the table below was prepared and incubated 
overnight at 37°C. Afterwards DNA was purified by NucleoSpin® Gel and PCR 
clean-up: a 250 μl NTI Buffer was added to the reaction mixture and loaded in a 
NucleoSpin® Gel and PCR clean-up column that was centrifuged at 11000 rpm for 
30 seconds. The column was washed twice with a 700 μl NT3 Buffer and 
centrifuged at 11000 rpm for 1 minute. After centrifugation DNA was eluted with a 
20 μl NE Buffer. Then cRNA concentration was measured by taking 1 μl of cRNA in 
69μl water using an Eppendorf Biophotometer (Hamburg, Germany). Finally, to 
confirm quality of generated cRNA its quality was checked by gel electrophoresis. 
 
           Table 3: Reaction mixture used to linearize DNA plasmid 
 
Reaction mixture Quantity 
10 X Buffer 5 µl 
Plasmid DNA (10 µg) Depends on DNA concentration 
Restriction enzyme (20 U) 2 µl 
Water Fill till reach a total volume of 25 µl 
 
 
 
3.1.2  cRNA  synthesis 
The linearized DNA produced by the method mentioned above was used as a 
template to generate cRNA. The reaction mixture listed below was put in a sterile 
eppendorf tube. 
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Table 4: Reaction mixture used to synthesize RNA from the linearized DNA. 
 
Reaction mixture Quantity 
10 X Buffer 2.5 µl 
rNTPs 1 µl 
Cap analog 2.5 µl 
RNAse inhibitor 1 µl 
Water Fill till reach a total volume of 25 µl 
 
 
The reaction mixture was gently spun and the appropriate RNA polymerase was 
added and spun again. RNA polymerases T7 or T3 or Sp6 were used, and the 
mixture was then incubated at 37°C for 2 hours, 5 μl of DNAse was added in the 
reaction mixture afterwards to remove the possible DNA contamination. Finally the 
reaction mixture was incubated at 37°C for 15 minutes under continuous shaking. 
 
Table 5: RNA polymerases used to prepare cRNA and amount of cRNA 
injected into oocytes. 
 
 
Protein 
 
RNA polymerase 
 
cRNA 
(ng/oocytes) 
 
Exp. time (days) 
 
Kv1.3 
 
Sp6 
 
2.5 ng 
 
3 
 
Kv1.5 
 
T3 
 
2.5 ng 
 
3 
 
Kir2.1 
 
T7 
 
10 ng 
 
3 
 
VP1 
 
T7 
 
10 ng 
 
3 
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H153AVP1 
 
T7 
 
10 ng 
 
3 
 
To purify the generated RNA, 129 μl of phenol chloroform mixture was mixed with 
100μl of DEPC water and was added in an eppendorf and centrifuged at 11000 
rpm for 5 minutes. After that, the upper inorganic phase was carefully taken into a 
new eppendorf tube, 12.5 μl of 3 M sodium acetate (pH 5.2) was added, as well as 
375 μl of 100% ethanol and then mixed and further incubated at -70°C for at least 
30 minutes. 
After incubation, the mixture was centrifuged at 20000 rpm for 15 minutes at 4°C. 
The supernatant was removed and the pellet was washed with 500 μl of 70% 
ethanol. Finally the pellet was left to dry in a dryer machine for 5 minutes and 
reconstituted in 40 μl of DEPC water and mixed again. Then cRNA concentration 
was measured by taking 1 μl of cRNA in 69 μl water using an Eppendorf 
Biophotometer (Hamburg, Germany). Finally, to confirm the quality of generated 
cRNA its quality was checked by gel electrophoresis. All the cRNA was provided 
by the department of Molecular Biology. 
 
3.2  Xenopus Laevis oocyte preperation 
The Xenopus Laevis female frog was anesthetized by immersion in a solution 
containing 0.1% ethyl 3-aminobenzoate methanesulfonate salt (Tricain) before the 
operation and the frogs was laid during operation on an absorbent paper coated 
with the solution in order to increase the duration of the effect of the Tricain.   
A small longitudinal incision (around 1-2 cm) was made in the lower abdomen for 
careful cutting of several pieces of the ovarian lobes and then the oocyte bags 
were extracted into small portions to avoid contamination through the Xenopus 
skin. Surgical blanket was placed at the operation incision and all the surgical 
instruments were properly sterilized as a protective measure. 
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The oocyte bags were put in a Petri dish containing the calcium free solution (OR2) 
for further separation, cleaning and preparation. The incision was cleaned properly 
and closed with reabsorbant stitches. The internal tissues mainly muscles and the 
external tissues (skin) were closed separately to aid the healing process.  
The Xenopus laevis frog was taken back to a provisional cage and was washed 
several times to be cleaned from possible traces of residual anaesthesia. After 30 
minutes of continuous washing when the frog recovered its reflexes and 
movement, it was washed two additional times. The frog was returned to the 
aquarium after the total recovery of its reflexes. 
The oocyte bags were extracted manually and divided into smaller groups to 
facilitate their digestion by the collagenase. The collagenase solution was prepared 
at a concentration of 2 mg/ml in OR2 and the oocytes were placed in a 50 ml 
Falcon tube containg collagenase recoated by aluminium foil to avoid external light 
interference. The duration of the digestion process was about 2-3 hours, 
depending of the digestion procedure, the frog, or the times that this frog was 
already operated. After the second hour of digestion, the oocytes were periodically 
visualized under the microscope every 30 minutes to check the status of the 
oocytes and to avoid excessive digestion by the collagenase. When the oocytes 
were determined to be ready for selection and injection, they were washed twice 
with OR2 and then with the ND-96 with antibiotics solution (ND96-A).The oocytes 
were then stored in a petri dish containing 3-3.5 ml of ND96-A. These stored 
oocytes can survive till 5-6 days if the petri dish containing the oocytes is kept in an 
incubator at a temperature of 17° C and the dead cells are removed and the media 
is changed periodically. The oocytes in growing stage V-VI, with a clear 
differentiation between poles, were selected for further experiments. All the cRNA 
injections were done at the same day of the operation. 
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The cRNA injections were done with a Nanoinjector 2000, previously configured for 
the suitable volume. A manually prepared borosilicate capillary was used for cRNA 
injection. After cutting the capillary edge and allowing a diameter of about 10-20 
µm at the end, the capillary was manually filled with paraffin oil and afterwards 
inserted into the microinjector. Careful attention was made all the time to avoid 
accidental contamination by cleaning the working place, using sterile pipettes, 
gloves, and DEPC water to dilute stock cRNA preparations. Oocytes injected with 
cRNA were stored in Petri dishes containing 3 -3.5 ml of sterilized ND96-A solution 
in an incubator at a temperature of 17° C for 3 days until having considerable 
expression of the injected cRNA.  
 
3.3 Potassium channels current recording in Xenopus laevis 
oocytes with Two electrode voltage clamp (TEVC) 
Two electrode voltage clamp (TEVC) is an important electrophysiological technique 
which depends on clamping the membrane potential of Xenopus Laevis oocytes to 
several voltage steps or fixing it to one holding potential in order to measure and 
record the charged particles movement across the membrane through ion 
channels, electrogenic transporters or pumps which were heterologously 
expressed in the plasma membrane of Xenopus oocytes.  
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Figure 5: An illustrative scheme for steps needed to measure with the two electrode 
voltage clamp technique (TEVC) in Xenopus oocytes. 
 
The two electrode voltage clamp measurement is achieved by introducing two 
glass microelectrodes inside the oocyte to reach the intracellular compartment. The 
first electrode records the membrane potential and the second electrode is the 
current injecting electrode. The signal recorded by the recording electrode reaches 
a feedback amplifier to compare it to the voltage clamp command set by a 
generator. The difference between these two signals is injected forward through 
the current injecting electrode to the intracellular leaflet of the Xenopus Laevis 
oocytes and back through the cell membrane to the reference electrode to 
complete the circuit. The deflection from the baseline is quantified and visualized 
as an electrogenic activity of the ion channels, transporters or pumps. The 
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reference electrodes are made of silver and coated with a silver chloride (AgCl) 
coating, whereas the microelectrodes are filled with KCl (3M) and connected to the 
feedback amplifier. The setup is covered by Grounded Faraday cage to prevent 
against possible external noise currents. Vibration and mechanical noise are 
reduced by using Pneumatic anti-vibration stage. The electrode potential was set 
to 0 mV after immersion in the bath solution and just before introducing the 
electrodes inside the oocytes. Under low magnification stereomicroscope (5-20X), 
oocytes were impaled with glass capillaries at opposite poles using 
micromanipulators. 
For Kv1.3 and Kv1.5 experiments, Xenopus oocytes were prepared as previously 
described (257), cRNA encoding Kv1.3 (2.5ng) or Kv1.5 (2.5ng), VP1 (10 ng) and 
H153AVP1(10ng) was injected on the same day of preparation of the Xenopus 
oocytes. All experiments were performed at room temperature (about 22° C) 3 days 
after the injection (258, 259). Two-electrode voltage clamp recordings were 
performed at a holding potential of -100 mV. The currents were recorded following 2 
second depolarizing pulses ranging from −80 to +50 mV in 10-mV and 15-s or 20-s 
increments from a holding potential of −100 mV. The data were filtered at 1 kHz and 
recorded with a Digidata 1322A A/D-D/A converter and ClampexV .9.2 software for 
data acquisition (Axon Instruments). The analysis of the data was performed with 
Clampfit 9.2 (Axon Instruments) software (260, 261). The oocytes were maintained 
at 17°C in ND96-A solution. The control superfusate (ND96) contained 96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2,1 mM MgCl2 and 5 mM HEPES, pH was adjusted 
to 7.4 by addition of NaOH (262). The flow rate of the superfusion was 20 ml/min, 
and a complete exchange of the bath solution was reached within about 10 s (263, 
264). 
 
To investigate whether the effect of VP1 on Kv1.3 or Kv1.5 is modified by 
actinomycin, Kv1.3 or Kv1.5 was expressed in Xenopus oocytes with additional 
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expression of VP1 in the presence of actinomycin (10 µM, added 36 hours prior to 
the experiment). 
To investigate whether Lysophosphatidylcholine affect the activity of Kv1.3 and Kv1.5 
K channels, Xenopus oocytes expressing Kv1.3 or Kv1.5 were treated with 
lysophosphatidylcholine (1µg/ml)  for 10 minutes.  
 
For Kir2.1 experiments, Xenopus oocytes were prepared as previously described 
(257, 265). cRNA encoding Kir2.1(10ng), VP1 (10 ng) and H153AVP1(10ng) was 
injected on the same day of preparation of the Xenopus oocytes (266, 267). All 
experiments were performed at room temperature (about 22° C) 3 days after the 
injection (268). In two-electrode voltage clamp experiments Kir2.1 currents were 
elicited every 20 s with 1 s pulses from -150 mV to +30 mV applied from a holding 
potential of -60 mV. The data were filtered at 1 kHz and recorded with a Digidata 
1322A A/D-D/A converter and ClampexV.9.2 software for data acquisition (Axon 
Instruments) (269, 270). The analysis of the data was performed with Clampfit 9.2 
(Axon Instruments) software (271, 272). The oocytes were maintained at 17°C in 
ND96-A solution. The control superfusate (ND96) contained 96 mM NaCl, 5 mM 
KCl, 1.8 mM CaCl2,1 mM MgCl2 and 5 mM HEPES, pH was adjusted to 7.4 by 
addition of NaOH (256). The flow rate of the superfusion was 20 ml/min, and a 
complete exchange of the bath solution was reached within about 10 s (273, 274). 
To test whether Lysophosphatidylcholine affect the activity of Kir2.1 K+ channels, 
Xenopus oocytes expressing Kir2.1 were treated with lysophosphatidylcholine 
(1µg/ml) for 10 minutes. 
To test whether the effect of VP1 expression or lysophosphatidylcholine treatment 
could be mimicked by inhibition of the Na+/K+ ATPase with Ouabain. Kir2.1 
expressing oocytes were treated with Ouabain (0.1 mM) for 10 minutes. 
To test whether the inhibition of Na+/K+ ATPase was required for the inhibitory 
effect of lysophosphatidylcholine on Kir2.1. The Kir2.1 expressing oocytes were 
treated either with lysophosphatidylcholine (1µg/ml) alone or with both 
lysophosphatidylcholine (1µg/ml) and Ouabain (0.1 mM) for 10 minutes. 
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3.4 Statistical analysis 
Data are provided as means ± SEM, n represents the number of oocytes 
investigated. All experiments were repeated with at least 3 batches of oocytes; in all 
repetitions qualitatively similar data were obtained. Data were tested for significance 
using analysis of variance (ANOVA) or t-test, as appropriate. Results with p < 0.05 
were considered statistically significant. 
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4. Results 
4.1  Regulation of Kv1.3 by VP1 
4.1.1 Inhibition of Kv1.3 currents in Kv1.3 expressing Xenopus oocytes by 
coexpression of VP1 but not of H153AVP1  
 
The present study explored the impact of parvovirus B19 capsid protein VP1 on 
Kv1.3 K+-channel activity. In order to test whether VP1 regulate the Kv1.3 K+ 
current, Kv1.3 was expressed in Xenopus oocytes with or without additional 
expression of VP1 or the H153AVP1 mutant lacking functional PLA2 activity. K+ peak 
currents taken as a measure of K+ channel activity.  
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Figure 6: normalized I/V curve of Kv1.3 K+ current with and without Coexpression of 
VP1 or the PLA2-negative H153AVP1 mutant 
Arithmetic means ± SEM (n =9-24) of the normalized depolarization-induced Kv1.3 peak 
current as a function of voltage in Xenopus oocytes injected with water (black squares), or 
with cRNA encoding Kv1.3 alone (white circles) or with cRNA encoding both, Kv1.3 and 
VP1 (black circles) or with cRNA encoding Kv1.3 and PLA2-negative VP1 mutant (grey 
circles). Peak currents were normalized to the mean peak current at +50 mV in Xenopus 
oocytes injected with cRNA encoding Kv1.3. *** (p<0.001) indicates statistically significant 
difference from Xenopus oocytes injected with cRNA encoding Kv1.3 (separated unpaired 
student t test). 
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Figure 7: effect of VP1 co-expression on K+ currect in Kv1.3 expressing 
Xenopus oocytes 
A.Original tracings recorded in Xenopus oocytes injected with  water (i), with cRNA encoding 
Kv1.3 alone (ii) with cRNAs encoding both, Kv1.3 and VP1 (iii) and with cRNA encoding both, 
Kv1.3 and the PLA2-negative H153AVP1 mutant (iv). The currents were recorded following 2 
second depolarizing pulses ranging from −80 to +50 mV in 10 mV and 15 second 
increments from a holding potential of −100 mV.B.Arithmetic means ± SEM (n = 9-24) of the 
normalized Kv1.3 peak current at +50 mV in Xenopus oocytes injected with water (dotted 
bar), with cRNA encoding Kv1.3 alone (white bar) with cRNA encoding both, Kv1.3 and VP1 
(black bar) or with cRNA encoding Kv1.3 and PLA2-negative VP1 mutant (grey bar). *** 
indicates statistically significant (p<0.001) difference from Xenopus oocytes injected with 
cRNA encoding Kv1.3 (ANOVA-one way).  
 
As shown in Figure 7, K+ current was low in Xenopus oocytes injected with water. 
Expression of Kv1.3 resulted in a strong current, which was significantly decreased 
by coexpression of VP1. In contrast, coexpression of the H153AVP1 mutant lacking 
PLA2 activity did not significantly modify Kv1.3 currents. As a result, in Kv1.3 
expressing Xenopus oocytes the K+ current was significantly higher following 
coexpression of H153AVP1 than following coexpression of VP1  
 
4.1.2  Inhibition of K+-current in Kv1.3 expressing Xenopus oocytes by VP1 Co- 
expression in presence of D-actinomycin 
 
In order to test, whether the effect of VP1 required transcription, additional 
experiment was performed in the presence of actinomycin (10 µM, added 36 hours 
prior to the experiment), Kv1.3 was expressed in Xenopus oocytes with additional 
expression of VP1 in the presence of actinomycin 
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Figure 8: effect of VP1 co-expression on currect in Kv1.3 expressing Xenopus 
oocytes in the presence of D-Actinomycin 
A. Original tracings recorded in oocytes injected with cRNA encoding Kv1.3 alone (i) or with 
cRNA encoding both, VP1 and Kv1.3 (ii), each with prior 36 hours treatment with 10 µM D-
actinomycin. The currents were recorded following 2s depolarizing pulses ranging from −80 
to +50 mV in 10 mV and 15 s increments from a holding potential of −100 mV. 
B. Arithmetic means ± SEM (n = 19-20) of the normalized K+-peak current following a 
depolarization from −80 to +50 mV  in oocytes injected with cRNA encoding Kv1.3 alone with 
prior 36 hours treatment with 10 µM D-actinomycin (white bar) or with cRNA encoding both, 
VP1and Kv1.3 (black bar), each with prior 36 hours treatment with 10 µM D-actinomycin. ** 
indicates statistically significant (p<0.01) difference from absence of VP1 (unpaired student t- 
test).  
 
As shown in Figure 8, even in the presence of actinomycin (10 µM, added 36 hours 
prior to the experiment) the coexpression of VP1 with Kv1.3 decreased the K+ 
current in Kv1.3 expressing oocytes. Thus, the effect of VP1 on Kv1.3 did not 
require transcription.  
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4.1.3 Inhibition of K+-channel activity in Kv1.3 expressing Xenopus oocytes by 
lysophosphatidylcholine 
 
Phospholipase A2 (PLA2) of VP1 is known to generate lysophosphatidylcholine. Thus, 
additional experiment was performed to explore whether lysophosphatidylcholine influences 
K+ currents in Kv1.3 expressing Xenopus oocytes, Kv1.3 expressing oocytes were treated 
with lysophosphatidylcholine(1µg/ml)  for 10 minutes  
 
Figure 9: effect of Lysophosphatidylcholine on K+ currect in Kv1.3 expressing 
Xenopus oocytes 
A. Original tracings recorded in oocytes injected with cRNA encoding Kv1.3 alone in the 
absence (i) or presence (ii) of lysophosphatidylcholine (1 μg/ml). The currents were recorded 
following 2s depolarizing pulses ranging from −80 to +50 mV in 10mV and 15 s increments 
from a holding potential of −100 mV. 
B. Arithmetic means ± SEM (n = 16) of the normalized K+-peak current following a 
depolarization from -80 mV to +50 mV in oocytes injected with cRNA encoding Kv1.3 alone in 
the absence (white bar) and presence (black bar) of lysophosphatidylcholine (1 μg/ml). * 
indicates statistically significant (p<0.05) difference from absence of lysophosphatidylcholine 
(unpaired student t test).  
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As shown in Figure 9, treatment of Kv1.3 expressing Xenopus oocytes with 
lysophosphatidylcholine (1µg/ml) for 10 minutes was indeed followed by a decrease 
of K+ currents. 
 
4.2  Regulation of Kv1.5 by VP1 
 
4.2.1 Inhibition of Kv1.5 K+ currents in Kv1.5 expressing Xenopus oocytes by 
coexpression of VP1 but not of H153AVP1  
 
The second part of study explored the impact of the parvovirus B19 capsid protein 
VP1 on Kv1.5 K+ channel activity. In order to test whether VP1 regulate the Kv1.5 
K+ current, Kv1.5 was expressed in Xenopus oocytes with or without additional 
expression of VP1 or the H153AVP1 mutant lacking functional PLA2 activity. K+-peak 
currents taken as a measure of K+ channel activity 
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Figure 10: normalized I/V curve of KV1.5 K+ current with and without Coexpression 
of VP1 or the PLA2-negative H153AVP1 mutant 
Arithmetic means ± SEM (n =3-26) of the normalized depolarization induced Kv1.5 peak 
current as a function of voltage in Xenopus oocytes injected with water (black squares), or 
with cRNA encoding Kv1.5 alone (white circles) or with cRNA encoding both, Kv1.5 and 
VP1 (black circles) or with cRNA encoding Kv1.5 and PLA2-negative VP1 mutant (grey 
circles). Peak currents were normalized to the mean peak current at +50 mV in Xenopus 
oocytes injected with cRNA encoding Kv1.5. *** (p<0.001) indicates statistically significant 
difference from Xenopus oocytes injected with cRNA encoding Kv1.5 (separated unpaired 
student t tests). 
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Figure 11: effect of VP1 co-expression on K+ currect in Kv1.5 expressing 
Xenopus oocytes 
A.Original tracings recorded in oocytes injected with  water (i), with cRNA encoding Kv1.5 
alone (ii) with cRNAs encoding both, Kv1.5 and VP1 (iii) and with cRNA encoding both, Kv1.5 
and the PLA2-negative H153AVP1 mutant (iv). The currents were recorded following 2 second 
depolarizing pulses ranging from −80 to +50 mV in 10 mV and 20 second increments from 
a holding potential of −100 mV.B.Arithmetic means ± SEM (n =3-26) of the normalized Kv1.5 
-peak current at +50 mV in Xenopus oocytes injected with  water (dotted bar), with cRNA 
encoding Kv1.5 alone (white bar) with cRNA encoding both, Kv1.5 and VP1 (black bar) and 
with cRNA encoding both, Kv1.5 and PLA2-negative VP1 mutant (grey bar). ** indicates 
statistically significant (p<0.01) difference from Xenopus oocytes injected with cRNA 
encoding Kv1.5 (ANOVA-one way).  
 
As shown in Figure 11, The K+ current in Xenopus oocytes expressing Kv1.5 was 
significantly decreased by coexpression of VP1. Coexpression of the H153AVP1 
mutant lacking PLA2 activity did not significantly modify Kv1.5 currents. The K+ 
current in Kv1.5 expressing Xenopus oocytes was thus significantly higher 
following coexpression of H153AVP1 than following coexpression of VP1. 
 
4.2.2 Inhibition of K+ current in Kv1.5 expressing Xenopus oocytes by VP1 
coexpression in presence of D-actinomycin 
 
In order to test, whether the effect of VP1 required transcription, additional 
experiments were performed in the presence of actinomycin (10 µM, added 36 
hours prior to the experiment). Kv1.5 was expressed in xenopus oocytes with 
additional expression of VP1 in the presence of actinomycin.  
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Figure 12: effect of VP1 co-expression on currect in Kv1.5 expressing Xenopus 
oocytes in the presence of D-Actinomycin 
A. Original tracings recorded in oocytes injected with cRNA encoding Kv1.5 alone (i) or with 
cRNA encoding both, VP1 and Kv1.5 (ii), each with prior 36 hours treatment with 10 µM D-
actinomycin. The currents were recorded following 2s depolarizing pulses ranging from −80 
to +50 mV in 10mV and 20 s increments from a holding potential of −100 mV. 
B. Arithmetic means ± SEM (n = 18) of the normalized K+-peak current following a 
depolarization from -80 mV to +50 mV in oocytes injected with cRNA encoding Kv1.5 alone 
(white bar) or with cRNA encoding both,Kv1.5 and VP1 (black bar), each with prior 36 hours 
treatment with 10 µM D-actinomycin. *** indicates statistically significant (p<0.001) difference 
from absence of VP1 (unpaired student t- test).  
 
As shown in Figure 12, even in the presence of actinomycin (10 µM, added 36 
hours prior to the experiment), the coexpression of VP1 decreased the K+ current 
in Kv1.5 expressing oocytes. Thus, the effect of VP1 on Kv1.5 did not require 
transcription.  
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4.2.3 Inhibition of K+channel activity in Kv1.5 expressing Xenopus oocytes by 
lysophosphatidylcholine 
 
PLA2 of VP1 is known to generate lysophosphatidylcholine. Thus, additional 
experiments were performed to test whether lysophosphatidylcholine influences K+ 
currents in Kv1.5 expressing Xenopus oocytes. Kv1.5 expressing oocytes were 
treated with lysophosphatidylcholine (1µg/ml) for 10 minutes.  
 
 
 
 
Figure 13: effect of Lysophosphatidylcholine on K+ currect in Kv1.5 expressing 
Xenopus oocytes 
A. Original tracings recorded in oocytes injected with cRNA encoding Kv1.5 alone in the 
absence (i) or presence (ii) of lysophosphatidylcholine (1 μg/ml). The currents were recorded 
following 2s depolarizing pulses ranging from −80 to +50 mV in 10mV and 20 s increments 
from a holding potential of −100 mV. 
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B. Arithmetic means ± SEM (n = 14-16) of the normalized K+-peak current following a 
depolarization from -80 mV to +50 mV in oocytes injected with cRNA encoding Kv1.5 alone in 
the absence (white bar) and presence (black bar) of lysophosphatidylcholine (1 μg/ml). ** 
indicates statistically significant (p<0.01) difference from absence of lysophosphatidylcholine 
(unpaired student t test).  
 
As shown in Figure 13, treatment of Kv1.5 expressing Xenopus oocytes with 
lysophosphatidylcholine (1µg/ml) for 10 minutes was indeed followed by a decrease 
of K+ currents.  
 
4.3  Regulation of Kir2.1 by VP1 
 
4.3.1 Inhibition of K+ currents in Kir2.1 expressing Xenopus oocytes by 
coexpression of VP1 but not of H153AVP1 
 
The third part of study explored, whether coexpression of parvovirus B19 capsid 
protein VP1 influences the activity of Kir2.1 K+-channels. In order to test whether 
VP1 regulate the Kir2.1 K+ current, Kir2.1 was expressed in Xenopus oocytes with 
or without additional expression of VP1 or the H153AVP1 mutant lacking functional 
PLA2 activity. Inwardly rectifying K+ peak currents was taken as a measure of K+-
channel activity 
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Figure 14: normalized I/V curve of KV1.5 K+ current with and without Coexpression 
of VP1 or the PLA2-negative H153AVP1 mutant 
Arithmetic means ± SEM (n = 6-22) of the normalized Kir2.1 current as a function of 
voltage in Xenopus oocytes injected with water (black squares), or with cRNA encoding 
Kir2.1 alone (white circles) or with cRNA encoding both, Kir2.1 and VP1 (black circles) or 
with cRNA encoding Kir2.1 and PLA2-negative VP1 mutant (grey circles). Peak currents 
were normalized to the mean peak current at -150 mV in Xenopus oocytes injected with 
cRNA encoding Kir2.1. *** (p<0.001) indicates statistically significant difference from 
Xenopus oocytes injected with cRNA encoding Kir2.1 (separated unpaired student t test). 
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Figure 15: Effect of VP1 co-expression on K+ currect in Kir2.1 expressing 
Xenopus oocytes 
A.Original tracings recorded in Xenopus oocytes injected with  water (i), with cRNA encoding 
Kir2.1 alone (ii) with cRNAs encoding both, Kir2.1 and VP1 (iii) and with cRNA encoding both, 
Kir2.1 and the PLA2-negative H153AVP1 mutant (iv). The currents were elicited every 20 s 
with 1 s pulses from -150 mV to +30 mV applied from a holding potential of -60 mV. 
B.Arithmetic means ± SEM (n = 6-22) of the normalized Kir2.1 peak current at -150 mV in 
Xenopus oocytes injected with  water (dotted bar), with cRNA encoding Kir2.1 alone (white 
bar) with cRNA encoding both, Kir2.1 and VP1 (black bar) or with cRNA encoding Kir2.1 and 
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H153AVP1 mutant (grey bar). *** (p< 0.001) indicates statistically significant difference from 
Xenopus oocytes injected with cRNA encoding Kir2.1 alone, # (p< 0.05) indicates 
statistically significant difference from Xenopus oocytes injected with cRNA encoding wild 
type VP1 (ANOVA-one way).  
As shown in Figure 15, Inwardly rectifying currents were low in Xenopus oocytes 
injected with water. Expression of Kir2.1 resulted in a strong inwardly rectifying 
current (IK). Coexpression of wild type VP1 was followed by a marked decline of IK. 
In contrast coexpression of the H153AVP1 mutant lacking functional PLA2 activity, 
did not significantly modify Kir2.1 currents. Accordingly, the K+ current was 
significantly higher following coexpression of Kir2.1 with H153AVP1 than following 
coexpression of Kir2.1 with VP1.  
 
4.3.2  Inhibition of K+-channel activity in Kir2.1 expressing Xenopus oocytes by 
lysophosphatidylcholine 
 
As PLA2 of VP1 is known to generate lysophosphatidylcholine, additional 
experiments were performed to test whether lysophosphatidylcholine influences K+ 
currents in Kir2.1 expressing Xenopus oocytes. Kir2.1 expressing oocytes were 
treated with lysophosphatidylcholine (1µg/ml) for 10 minutes. 
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Figure 16: effect of lysophosphatidylcholine on K+ current in Kir2.1 expressing 
Xenopus oocytes  
A. Original tracings recorded in oocytes injected with cRNA encoding Kir2.1 alone in the 
absence (i) or presence (ii) of lysophosphatidylcholine (1 μg/ml). The currents were elicited 
every 20 s with 1 s pulses from -150 mV to +30 mV applied from a holding potential of -60 
mV.B. Arithmetic means ± SEM (n = 18) of the normalized K+-peak current in oocytes 
injected with cRNA encoding Kir2.1 alone in the absence (white bar) and presence (black 
bar) of lysophosphatidylcholine (1 μg/ml). * indicates statistically significant (p<0.05) 
difference from absence of lysophosphatidylcholine (unpaired student t test).  
 
As shown in Figure 16, the treatment of Kir2.1 expressing Xenopus oocytes with 
lysophosphatidylcholine (1µg/ml) within 10 minutes significantly decreased the K+ 
currents.  
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4.3.3  Inhibition of K+-channel activity in Kir2.1 expressing Xenopus oocytes by 
Ouabain 
Additional experiments were performed to test whether the effect of VP1 
expression or lysophosphatidylcholine treatment could be mimicked by inhibition of 
the Na+/K+ ATPase with Ouabain. In order to test whether effect of VP1 expression or 
lysophosphatidylcholine treatment could be mimicked by inhibition of the Na+/K+ 
ATPase with ouabain, Kir2.1 expressing oocytes were treated with Ouabain (0.1 mM) 
for 10 minutes 
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Figure 17: Effect of Ouabain on K+ current in Kir2.1 expressing Xenopus 
oocytes 
A. Original tracings recorded in oocytes injected with cRNA encoding Kir2.1 alone in the 
absence (i) or presence (ii) of ouabain (0.1 mM). The currents were elicited every 20 s with 
1 s pulses from -150 mV to +30 mV applied from a holding potential of -60 mV. 
B. Arithmetic means ± SEM (n = 18) of the normalized K+-peak current in oocytes injected 
with cRNA encoding Kir2.1 alone in the absence (white bar) and presence (black bar) of 
ouabain (0.1 mM). * indicates statistically significant (p<0.05) difference from absence of 
ouabain (unpaired student t test). 
As shown in Figure 17, the treatment of Kir2.1 expressing Xenopus oocytes with 
ouabain within 10 minutes significantly decreased the K+ currents 
 
4.3.4 Nonadditivity of lysophosphatidylcholine and ouabain on Kir2.1 K+ 
channel activity 
 
Further experiments tested, whether the inhibition of Na+/K+ ATPase was required 
for the inhibitory effect of lysophosphatidylcholine on Kir2.1. To this end, the Kir2.1 
expressing Xenopus oocytes were treated either with lysophosphatidylcholine 
(1µg/ml) alone or with both lysophosphatidylcholine (1µg/ml) and ouabain (0.1 mM) 
for 10 minutes. 
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Figure 18: Nonadditivity of lysophosphatidylcholine and ouabain on Kir2.1 K+ 
channel activity   
A. Original tracings recorded in oocytes injected with cRNA encoding Kir2.1 alone and 
treated for 10 minutes with lysophosphatidylcholine (1 μg/ml) (i) or with both, 
lysophosphatidylcholine (1µg/ml) and ouabain (0.1 mM)(ii). The currents were elicited every 
20 s with 1 s pulses from -150 mV to +30 mV applied from a holding potential of -60 mV. 
B. Arithmetic means ± SEM (n = 19) of the normalized K+-peak current in oocytes injected 
with cRNA encoding Kir2.1 alone in the presence of lysophosphatidylcholine  (1 μg/ml) (white 
bar) and presence (black bar) of both lysophosphatidylcholine (1µg/ml) and ouabain (0.1 
mM). 
As illustrated in Figure 18, the decline of IK in Kir2.1 expressing oocytes was similar 
following combined treatment with lysophosphatidylcholine (1µg/ml) and ouabain 
(0.1 mM) and following treatment with lysophosphatidylcholine alone. 
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5.  Discussion and Conclusion 
5.1 Regulation of Kv1.3 and Kv1.5 by parvovirus B19 capsid protein VP1 
Although the association between B19V infection and acute and chronic 
myocarditis has been revealed with the identification of myocardial endothelial cells 
as target cells (30, 33, 247, 275, 276) and the role of B19 as causative agent  in 
the development of endothelial and isolated left ventricle diastolic dysfunction has 
been discussed (76), little is known about the pathophysiological mechanisms 
involved (249). Endothelial rather than myocardial B19V was detected in fatal 
inflammatory cardiomyopathy (33, 34). 
 
It has been shown that parvovirus B19 capsid protein VP1 increase Ca2+ entry in 
the endothelial cells through activation of the store operated or capacitative Ca2+ 
channel (ICRAC), an effect which is mimicked by the PLA2 product 
lysophosphatidylcholine and abolished by an inactivating mutation of the PLA2-
encoding region of the VP1 protein (249). Similarly, VP1 has been shown to 
downregulate Na+/K+ ATPase, an effect is mimicked by the PLA2 product 
lysophosphatidylcholine and abolished by an inactivating mutation of the PLA2-
encoding region of the VP1 protein (250). 
 
The Xenopus oocytes expression system has played an important role in the study 
of cellular proteins because it is used for expression of transporters and ion 
channels and for functional screening for ion channels modulators (277). 
Xenopus oocytes expression system was first used for expression of cellular 
proteins in 1971, where it was revealed that Xenopus oocytes are able to 
synthesize haemoglobin following intracellular injection of the corresponding 
mRNA (278).  
 
In comparison to mammalian cell lines, Xenopus oocytes have a number of 
advantages as an expression system for cellular proteins. The cost of the frogs is 
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relatively low and frogs are easily maintained and reproduced in aquariums. 
Oocytes can be obtained many times from the same frog by partial ovarectomy 
and can survive outside the body of the frog for up to a month if conserved at 4 °C. 
The handling of the Xenopus oocytes is easy because they are big in size. 
Xenopus oocytes contain the necessary enzymes for the expression of a wide 
range of mammalian proteins (277). Following injection of cRNA into the oocyte, 
proteins are expressed after 1–2 days and functional studies of ion channels and 
receptors are easily performed using two-electrode voltage clamp technique. An 
important advantage is that most cRNAs are readily expressed without the need to 
develop a cell line, whereas there is often a delay from the cloning of a new 
receptor until it can be expressed in a mammalian cell line (277). 
 
Despite the advantages of the Xenopus oocytes expression system, this 
expression system has several disadvantages. The most important of these is 
whether ion channels expressed in Xenopus oocytes are assembled and behave in 
an identical fashion to those expressed in mammalian cells. The size of the 
Xenopus oocyte is large, which gives a relatively slow fluid exchange time around 
the oocyte compared to a mammalian cell, which can be a problem for recording 
fast desensitizing ligand gated channels in the oocytes. Another disadvantage is 
that each oocyte must be injected with cRNAs, which is slower than the 
simultaneous transfection of large numbers of mammalian cells (277), However, 
some studies showed similar results in Xenopus oocytes expression system and 
mammalian cells (250, 279-282). 
 
The present study was done to investigate whether parvovirus B19 capsid protein 
VP1 modifies the activity of Kv1.3 and Kv1.5 Potassium channels and to test 
whether the effect is is sensitive to inhibition of PLA2 and is mimicked by 
lysophosphatidylcholine using Xenopus oocytes expression system. Kv1.3 or 
Kv1.5 was expressed in the Xenopus oocytes with or without additional expression 
of VP1 and VP1 dead mutant (H153AVP1) lacking functional PLA2 activity. Two 
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electrode voltage clamp technique was used to measure the potassium current. 
The measurements showed inhibition of both Kv1.3 and Kv1.5 K+ current by VP1 
but not by VP1 dead mutant (H153AVP1) lacking functional PLA2 activity. 
Further experiments were done to test whether the effect of VP1 on Kv1.3 and 
Kv1.5 potassium current is mimicked by lysophosphatidylcholine, Kv1.3 or Kv1.5 
was expressed in Xenopus oocytes and treated by lysophosphatidylcholine 
(1µg/ml) for 10 minutes. Two electrode voltage clamp technique was used to 
measure the potassium current. The experiments showed inhibition of Kv1.3 and 
Kv1.5 K+ current by lysophosphosphatidylcholine which is generated by 
phospholipase A2 like motif of VP1 protein. 
 
The present observations reveal a novel action of the B19V capsid protein VP1, i.e. 
the downregulation of the voltage gated K+ channels Kv1.3 and Kv1.5. The effect 
requires an intact phospholipase A2-like motif (283, 284) in the VP1 protein. 
Mutation of the motif virtually abrogates the effect of VP1 on Kv1.3 and Kv1.5. The 
effect of VP1 on Ca2+ entry  (249) and Na+/K+ ATPase activity (250) similarly 
depended on phospholipase A2 activity and was similarly abolished following site 
directed mutation of the PLA2 motif, i.e. replacement of the histidine by alanine in 
the putative catalytic site (H153AVP1). Similar to what has been observed previously 
on the regulation of Ca2+ entry  (249) and Na+/K+ ATPase activity (250), the effect 
of VP1 expression on Kv1.3 and Kv1.5 channel activity was mimicked by 
lysophosphatidylcholine, a product of phospholipase A2.  
 
B19V enters myocardial endothelial cells (33, 34) and may thus trigger acute 
myocarditis resulting in a clinical course similar to myocardial infarction (33, 34). 
Inhibition of K+ channels could lead to cell swelling (285, 286) and could thus 
contribute to endothelial dysfunction. The effect is expected to be compounded by 
inhibition of Na+/K+-ATPase (250), which would dissipate the ion gradients across 
the cell membrane thus further compromizing the ability of the cell to maintain cell 
volume constancy (250). K+ exit through K+ channels generates a cell negative 
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potential difference across the cell membrane driving Cl- exit. Inhibition of K+ 
channels is expected to depolarize the cell membrane thus dissipating the electrical 
driving force for Cl- exit. As a result, downregulation of K+ channels is expected to 
trigger cellular accumulation of KCl with the respective osmotically obliged water and 
thus to swell the cells (285, 286). Cell swelling is further fostered by cellular NaCl 
accumulation, if Na+/K+ATPase activity is inhibited (250). 
 
Inhibition of Kv1.3 K+ channels may further affect cell proliferation, which, at least 
in some cell types, requires Kv1.3 channel activity (252, 253). Whether or not 
impaired endothelial cell proliferation may contribute to the pathophysiology of 
B19V infection remains to be shown. 
 
In conclusion, VP1 down-regulates the Kv1.3 and Kv1.5 K+ channel, an effect 
involving phospholipase A2 activity of the parvoviral B19 protein and genetration of 
lysophosphatidylcholine. The inhibition of endothelial K+ channels may lead to cell 
swelling and thus participate in the pathophysiology of endothelial dysfunction 
during parvovirus B19 infection. 
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Figure 19: Summary of regulation of Kv1.3 and Kv1.5 by VP1 
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5.2  Regulation of Kir2.1 by parvovirus B19 capsid protein VP1 
 
B19V is a worldwide infectious pathogen in humans as the estimated prevalence of 
IgG antibodies directed against B19V ranges from 2 to 15% in children at age of 1 
to 5 years old, 15 to 60% in children aged 6 to 19 years old, 30 to 60% in adults, 
and more than 85% in the geriatric population(35-38). 
 
B19V causes common infections (245) leading to diverse clinical entities, such as 
fifth disease (erythema infectiosum), hydrops fetalis and transient aplastic anaemia 
(25, 287). More importantly B19V infection is associated with myocarditis (246, 
247). 
 
It is known that the myocardial endothelium is as a target for parvovirus B19 in 
acute and chronic myocarditis (30, 33, 247, 275, 276) And it has been shown that   
B19V is a causative agent in  endothelial and left ventricle diastolic dysfunction 
(76), but the pathophysiological mechanisms involved are still not known(249). 
Parvovirus B19 genomes were detected in the endothelium of myocardial tissue 
predominantly of small intramyocardial arteries and venoles, but not in cardiac 
myocytes or epicardial coronaries in fatal inflammatory cardiomyopathy. The 
presence of B19V genomes is accompanied with expression of the adhesion 
molecule E-selectin, margination, adherence, penetration, and perivascular 
infiltration of the heart by T-lymphocytes and macrophages function (33, 34)  
 
It has been shown that parvovirus B19 capsid protein VP1 increase Ca2+ entry in 
the endothelial cells through activation of the store operated or capacitative Ca2+ 
channel (ICRAC), an effect which was mimicked by the PLA2 product 
lysophosphatidylcholine and abolished by an inactivating mutation of the PLA2-
encoding region of the VP1 protein (249). Similarly, VP1 has been shown to 
downregulate Na+/K+ ATPase, an effect was mimicked by the PLA2 product 
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lysophosphatidylcholine and abolished by an inactivating mutation of the PLA2-
encoding region of the VP1 protein (250).  
This study was done to investigate whether parvovirus B19 capsid protein VP1 
modifies the activity of inwardly rectifying Kir2.1 Potassium channels and to test 
whether the effect is is sensitive to inhibition of PLA2 and is mimicked by 
lysophosphatidylcholine using Xenopus oocytes expression system. Kir2.1 was 
expressed in the Xenopus oocytes with or without additional expression of VP1 
and VP1 dead mutant (H153AVP1) lacking functional PLA2 activity. Two electrode 
voltage clamp technique was used to measure the potassium current. The 
experiments have shown inhibition of Kir2.1 K+ current by VP1 but not by VP1 
dead mutant (H153AVP1) lacking functional PLA2 activity. 
Another set of experiments were done to test whether the effect of VP1 on Kir2.1 
K+ current is mimicked by lysophosphatidylcholine, Kir2.1 was expressed in 
Xenopus oocytes and was treated by lysophosphatidylcholine (1µg/ml) for 10 
minutes. Two electrode voltage clamp technique was used to measure the 
potassium current. These experiments have shown inhibition of Kir2.1 Potassium 
current by Lysophosphosphatidylcholine which is generated by phospholipase A2 
like motif of VP1 protein. 
 
The present observations disclose a novel effect of the B19V capsid protein VP1, 
i.e. the downregulation of the inwardly rectifying K+ channel Kir2.1. As shown 
previously for Kv1.3 and Kv1.5 channels (288), Ca2+ entry(249) and Na+/K+ 
ATPase activity (250), the effect of VP1 requires its phospholipase A2-like motif 
(21, 24). Loss of function mutation of the motif disrupts the effect of VP1 on Kir2.1. 
Again, similar to what has been observed previously on the regulation of voltage 
gated K+ channels (288), Ca2+ entry (249) and Na+/K+ ATPase activity (250), the 
effect of VP1 expression on Kir2.1 channel activity was mimicked by the vPLA2 
product lysophosphatidylcholine. 
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The effect of B19V on K+ channels could contribute to the triggering of endothelial 
dysfunction, as B19V enters myocardial endothelial cells (33, 34). Inhibition of K+ 
channels is expected to foster cell swelling (285, 286), as reduced K+ channel 
activity leads to impaired K+ exit, depolarization, Cl- entry and thus cellular 
accumulation of KCl with the respective osmotically obliged water swelling (285, 
286). The depolarization is further fostered by inhibition of Na+/K+-ATPase activity 
(250) with the resulting dissipation of the ion gradients across the cell membrane. 
 
The inhibition of Kir2.1 channels could at least partially result from the inhibitory 
effect of lysophosphatidylcholine on the Na+/K+-ATPase (250), as the channels are 
similarly downregulated by the Na+/K+-ATPase inhibitor ouabain. Inwardly rectifying 
K+ channels have previously been shown to be highly sensitive to Na+/K+-ATPase 
activity and to be rapidly down regulated following pump inhibition (239).  
 
Since functional expression of classical Kir channels provides the driving force for 
Ca2+ influx through Ca2+-permeable channels by seting the Eres of endothelial cells 
to a negative potential, inhibition of endothelial Kir channels is expected to inhibit 
both flow induced Ca2+ influx and vasodilatation caused by Ca2+ dependent 
production of Nitric Oxide (224, 225).  
 
In conclusion, VP1 down-regulates the inwardly rectifying K+ channel Kir2.1, an 
effect involving phospholipase A2 activity of the parvoviral B19 protein, 
lysophosphatidylcholine formation, and inhibition of Na+/K+-ATPase activity. The 
inhibition of endothelial K+ channels may lead to cell swelling and thus participate 
in the pathophysiology of endothelial dysfunction during parvovirus B19 infection. 
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                          Figure 20: Summary of regulation of Kir2.1 by VP1 
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6. Summary 
 
Parvovirus B19 (B19V) can cause inflammatory cardiomyopathy and endothelial 
dysfunction. Pathophysiological mechanisms involved include lysophosphatidylcholine 
producing phospholipase A2 (PLA2) activity of the B19V capsid protein VP1. Most 
recently, VP1 and lysophosphatidylcholine have been shown to inhibit Na+/K+ 
ATPase. The present study explored whether VP1 modifies the activity of Kv1.3, 
Kv1.5 and Kir2.1 K+ channels. 
The first part of study explored, whether expression of VP1 modifies the activity of 
Kv1.3 and Kv1.5 K+ channels. cRNA encoding Kv1.3 or Kv1.5 was injected into 
Xenopus oocytes without or with cRNA encoding VP1,which was isolated from a 
patient suffering from fatal B19V induced myocarditis or the VP1 mutant H153AVP1 
lacking a functional PLA2 activity. K+ channel activity was determined by dual 
electrode voltage clamp. Injection of cRNA encoding Kv1.3 or Kv1.5 into Xenopus 
oocytes was followed by appearance of Kv K+ channel activity, which was 
significantly decreased by additional injection of cRNA encoding VP1, but not by 
additional injection of cRNA encoding PLA2-negative VP1 mutant H153AVP1. The 
effect of VP1 on Kv current was not significantly modified by transcription inhibitor 
actinomycin (10 µM for 36 hours) but was mimicked by lysophosphatidylcholine (1 
μg/ml). 
The B19V capsid protein VP1 inhibits host cell Kv channels, an effect at least 
partially due to phospholipase A2 (PLA2) dependent formation of 
lysophosphatidylcholine.  
The second part of study explored, whether expression of VP1 influences the 
activity of the inwardly rectifying Kir2.1 K+ channels. cRNA encoding Kir2.1 was 
injected into Xenopus oocytes without or with cRNA encoding VP1 or the VP1 
mutant H153AVP1. K+ channel activity was determined by dual electrode voltage 
clamp. Injection of cRNA encoding Kir2.1 into Xenopus oocytes was followed by 
appearance of inwardly rectifying K+ channel activity (IK), which was significantly 
decreased by additional injection of cRNA encoding VP1, but not by additional 
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injection of cRNA encoding H153AVP1. The effect of VP1 on IK was mimicked by 
lysophosphatidylcholine (1 μg/ml) and by inhibition of Na+/K+-ATPase with 0.1 mM 
ouabain. In the presence of lysophosphatidylcholine, IK was not further decreased 
by additional treatment with ouabain.  
The B19V capsid protein VP1 inhibits Kir2.1 channels, an effect at least partially 
due to phospholipase A2 (PLA2) dependent formation of lysophosphatidylcholine 
with subsequent inhibition of Na+/K+-ATPase activity. 
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7. Zusammenfassung 
Der Parvovirus B19 (B19V) kann entzündliche Kardiomyopathie und endotheliale 
Dysfunktion verursachen. Die beteiligten pathophysiologischen Mechanismen 
beinhalten die Lysophosphatidylcholin produzierende Phospholipase A2 (PLA2) 
Aktivität des B19V Capsidprotein VP1. So ist bereits gezeigt worden, dass VP1 
und Lysophosphatidylcholin die Na+ / K+ -ATPase hemmen. In der vorliegenden 
Arbeit wurde untersucht, ob VP1 die Aktivität der Kv1.3, Kv1.5 und Kir2.1 K+ 
Kanäle ändert. 
Im ersten Teil der Arbeit wurde untersucht, ob die Expression des VP1 die Aktivität 
von Kv1.3 und Kv1.5 K+ Kanäle verändert. Die cRNA des Kv1.3 oder Kv1.5 wurde 
in Xenopus-Oozyten sowohl mit als auch ohne cRNA des VP1 injiziert, welches 
von einem an B19V verstorbenen Myokarditispatienten stammte, und einer VP1-
Mutante H153AVP1 mit fehlenden funktionellen PLA2-Aktivität. Die K + -Kanal-
Aktivität wurde mittels der 2-Elektroden-Voltage-Clamp-Methode ermittelt. Die 
Injektion der Kv1.3 oder Kv1.5 cRNA in Xenopus Oozyten führte zum Auftreten der 
Aktivität des Kv-K+ -Kanals, durch zusätzliche Injektion der VP1-cRNA  signifikant 
welche verringert wurde. Dies konnte nicht nach der Injektion der PLA2-negative 
Mutante VP1 H153AVP1 beobachtet werden. Der Effekt von VP1 auf den Kv Strom 
wurde nicht signifikant durch den Transkriptionsinhibitor Actinomycin (36 Stunden 
10 & mgr; M) modifiziert und war ähnlich wie nach der Zugabe von 
Lysophosphatidylcholin (1 ug / ml) 
Das B19V Capsidprotein VP1 hemmt in der Wirtszelle die Kv-Kanäle, welche 
teilweise einen Effekt der Phospholipase A2 (PLA2) abhängigen Bildung auf 
Lysophosphatidylcholin hat. 
Im zweiten Teil der Arbeit wurde untersucht, ob die Expression des VP1 die 
Aktivität der einwärtsgerichteten Kir2.1 K + -Kanälen beeinflusst. Die Kir2.1 cRNA 
wurde sowohl mit als auch ohne VP1-cRNA oder mit der VP1-Mutante H153AVP1 in 
Xenopus-Oozyten injiziert. Die K+ -Kanal-Aktivität wurde mit der 2-Elektroden-
Voltage-Clamp-Methode ermittelt. Die Injektion der Kir2.1-cRNA in Xenopus-
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Oozyten führte zum Auftreten einer nach innen gleichgerichtenten K + -Kanal-
Aktivität (IK), die durch zusätzliche Injektion von codierter VP1-cRNA signifikant 
verringert war, jedoch nicht durch zusätzliche Injektion von H153AVP1-cRNA. Der 
Effekt von VP1 auf die IK war ähnlich wie nach der Zugabe von 
Lysophosphatidylcholin (1 ug / ml) und Hemmung der Na+/K+-ATPase mit 0,1 mM 
Ouabain. Der Ik Strom wurde unter Lysophosphatidylcholin nicht weiter durch 
Zugabe von Ouabain verringert. 
Das B19V Capsidprotein VP1 hemmt Kir2.1-Kanäle, ein Effekt der zumindest 
teilweise auf der Phospholipase A2 (PLA2) abhängigen Bildung von 
Lysophosphatidylcholin mit anschließender Hemmung der Na+ / K+ -ATPase-
Aktivität zurückzuführen ist. 
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